Skip to main content

Table 3 Grade 3–4 adverse events (CTCAE version 3.0, Concurrent chemoradiotherapy course N = 15, Consolidation chemotherapy course N = 14)

From: A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma

Toxicity grade 3–4

Concurrent chemoradiotherapy N (%)

Consolidation chemotherapy N (%)

Neutropenia

5 (33.3)

2 (14.3)

Anemia

2 (13.3)

3 (21.4)

Thrombocytopenia

2 (13.3)

1 (7.1)

Febrile neutropenia

1 (6.7)

0 (0.0)

Vomiting

2 (13.3)

0 (0.0)

Esophagitis

3 (20.0)

1 (7.1)

Transaminase

1 (6.7)

0 (0.0)

Pneumonitis

1 (6.7)

0 (0.0)

Creatinine

0

0 (0.0)